Specifically, the COMET‐LR and the combination model achieved a favorable sensitivity of 77.6% and 83.6% in stage I cancer cases, superior to AFP (50.7%) and PIVKA‐II alone (68.7%, Figure 3C). This evidence concerns the gene AFP and cancer.